Advertisement


Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

ASH 2025

Advertisement

Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increasea measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490). 



Related Videos

Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, on MDS: Research Highlights From ASH 2025

Guillermo Garcia-Manero, MD, of The University of Texas MD Anderson Cancer Center, reviews data from three abstracts in myelodysplastic syndromes (MDS) presented at this year’s meeting: outcomes from the phase III VERONA trial of venetoclax with azacitidine vs placebo with azacitidine in patients with treatment-naive intermediate- and higher-risk MDS (Abstract 235); safety and efficacy results from a phase Ib trial of a dual IRAK1/4 inhibitor in patients with relapsed/refractory lower-risk MDS (Abstract 489); and results from the phase II ASTX030-01 trial, showing pharmacokinetic, efficacy, and safety data of oral ASTX030 in patients with MDS (Abstract 491). 

Leukemia

Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant

Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516). 

Leukemia

Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)and could challenge the current treatment standard (Abstract 6). 

Myelodysplastic Syndromes

Brian Ball, MD, on Higher-Risk MDS: Bexmarilimab and Azacitidine

Brian Ball, MD, of City of Hope, presents updated results from the phase I/II BEXMAB study. They showed that the doublet had encouraging activity in patients with TP53-mutant, higher-risk MDS; translational data support the combination regimen’s potential for altering immune dysregulation in this subtype (Abstract 236). 

Multiple Myeloma

Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

Shahzad Raza, MD, of Cleveland Clinic, presents updated phase II results of the RedirecTT-1 trial, focusing on the efficacy and safety of talquetamab combined with teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease (Abstract 698). The study also received simultaneous publication in The New England Journal of Medicine.

Advertisement

Advertisement




Advertisement